Back to search
Pulmonary Alveolar Proteinosis (PAP)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Pulmonary Alveolar Proteinosis (PAP) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Pulmonary Alveolar Proteinosis (PAP) trials you may qualify forBackground: * Healthy people have white blood cells that protect them against bacteria, viruses, and fungi. However, some people have diseases which cause the…
Mutations in the MARS gene encoding methionyl-tRNA synthetase are responsible for a genetic form of alveolar proteinosis (PAP), but the pathophysiological mecha…
This is a prospective, randomized, open-label, long-term, phase 2 study of inhaled granulocyte/macrophage-colony stimulating factor following whole lung lavage…
The purpose of this study is to evaluate the therapeutic efficacy of inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteino…
Autoimmune pulmonary alveolar proteinosis (aPAP) is a respiratory disease characterized by massive deposition of pulmonary surfactant in the alveoli, involving…
By updating the chest HRCT scoring criteria of patients with pulmonary alveolar proteinosis, a new and more perfect system for evaluating the severity of alveol…
The purpose of this study is twofold: to assess routine cat scan (CT) imaging as a biomarker for removal of lipoprotein surfactant via lung lavage (where CT is…
The purpose of the study is to evaluate if inhaled granulocyte-macrophage colony stimulating factor delay the increase in alveolar-arterial oxygen difference, c…
The purpose of this study is to establish an efficient and economic treatment scheme by evaluation of the safety and efficacy of subcutaneous injection of low-d…